

## SAFETY DATA SHEETS

**This SDS packet was issued with item:**

078476885

N/A



# MATERIAL SAFETY DATA SHEET

Revision date: 05-Nov-2009

Version: 1.3

Page 1 of 7

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-212-573-2222

Emergency telephone number:  
CHEMTREC (24 hours): 1-800-424-9300  
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161  
Emergency telephone number:  
ChemSafe (24 hours): +44 (0)208 762 8322

**Material Name: Hydrocortisone Sodium Succinate for Injection**

Trade Name:	Solu-Cortef®
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product used as anti-inflammatory

## 2. HAZARDS IDENTIFICATION

Appearance: White to off-white powder  
Signal Word: WARNING

Statement of Hazard: Suspected of damaging the unborn child.

### Additional Hazard Information:

**Short Term:** May cause slight irritation ; May cause skin irritation. (based on components) . May be absorbed through the skin in harmful amounts. Central nervous system effects such as headache, dizziness, drowsiness, fatigue, and lack of muscular coordination can also occur. May cause stomach irritation, diarrhea, nausea, or vomiting.

**Long Term:** Animal studies have shown a potential to cause adverse effects on the fetus. However, occupational handling of this product is not expected to result in relevant exposures.

**Known Clinical Effects:** Effects on vision have been seen during clinical use. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual irregularities, facial hair growth, and mental changes. Clinical use may cause an increase in blood pressure (hypertension). Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

**EU Indication of danger:** Toxic to Reproduction: Category 3

**EU Hazard Symbols:**

Xn



**EU Risk Phrases:**

R63 - Possible risk of harm to the unborn child.  
Hazardous Substance. Non-Dangerous Goods.

**Australian Hazard Classification (NOHSC):**

## MATERIAL SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for  
Injection  
Revision date: 05-Nov-2009

Page 2 of 7

Version: 1.3

### 2. HAZARDS IDENTIFICATION

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Hydrocortisone Sodium Succinate	125-04-2	204-725-5	Repr.Cat.3;R63	91.3

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Sodium phosphate, monobasic	7558-80-7	231-449-2	Not Listed	*
Sodium phosphate, dibasic	7558-79-4	231-448-7	Not Listed	*

**Additional Information:** \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Hazardous Combustion Products:** Carbon dioxide, carbon monoxide

**Fire Fighting Procedures:** During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

## MATERIAL SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection  
Revision date: 05-Nov-2009

Page 3 of 7

Version: 1.3

### 6. ACCIDENTAL RELEASE MEASURES

<b>Health and Safety Precautions:</b>	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
<b>Measures for Cleaning / Collecting:</b>	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
<b>Measures for Environmental Protections:</b>	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
<b>Additional Consideration for Large Spills:</b>	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

<b>General Handling:</b>	Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
<b>Storage Conditions:</b>	Store as directed by product packaging.

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hydrocortisone Sodium Succinate  
Pfizer OEL TWA-8 Hr:

100µg/m<sup>3</sup>, Skin

<b>Analytical Method:</b>	Analytical method available for hydrocortisone. Contact Pfizer Inc for further information.
<b>Engineering Controls:</b>	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
<b>Environmental Exposure Controls:</b>	Refer to specific Member State legislation for requirements under Community environmental legislation.
<b>Personal Protective Equipment:</b>	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
<b>Hands:</b>	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
<b>Eyes:</b>	Wear safety glasses or goggles if eye contact is possible.
<b>Skin:</b>	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
<b>Respiratory protection:</b>	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

## MATERIAL SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection

Revision date: 05-Nov-2009

Page 4 of 7

Version: 1.3

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Powder	Color:	White to off-white
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solubility:	Soluble: Water		

### 10. STABILITY AND REACTIVITY

Stability:	Stable under recommended storage conditions. Solutions are unstable after 4 hours.
Conditions to Avoid:	Exposure to light
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers

### 11. TOXICOLOGICAL INFORMATION

General Information:	The information included in this section describes the potential hazards of the individual ingredients.
----------------------	---

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Hydrocortisone Sodium Succinate

Rat	Oral	LD 50	5000 mg/kg
Mouse	Oral	LD 50	5000 mg/kg
Rat	Subcutaneous	LD 50	449 mg/kg
Mouse	Subcutaneous	LD 50	>500 mg/kg
Rat	Intraperitoneal	LD 50	150 mg/kg

##### Sodium phosphate, dibasic

Rat	Oral	LD 50	17 g/kg
-----	------	-------	---------

##### Sodium phosphate, monobasic

Rat	Oral	LD 50	8290 mg/kg
-----	------	-------	------------

Acute Toxicity Comments:	A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.
--------------------------	--

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Hydrocortisone Sodium Succinate

Eye Irritation	Rabbit	Minimal
----------------	--------	---------

##### Sodium phosphate, dibasic

Eye Irritation	Rabbit	Mild
Skin Irritation	Rabbit	Mild

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Hydrocortisone Sodium Succinate

7 Day(s)	Mouse	Oral	140 mg/kg/day	LOAEL	Thymus
4 Day(s)	Mouse	Subcutaneous	100 mg/kg/day	LOAEL	Liver

100 MG PLAIN

## MATERIAL SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection  
Revision date: 05-Nov-2009

Page 5 of 7

Version: 1.3

### 11. TOXICOLOGICAL INFORMATION

11 Day(s)	Mouse	Subcutaneous	62 mg/kg/day	LOAEL	Endocrine system
2 Week(s)	Mouse	Subcutaneous	560 mg/kg/day	LOAEL	Liver Bone Marrow
85 Day(s)	Rat	Subcutaneous	175 mg/kg/day	LOAEL	Adrenal gland

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### Hydrocortisone Sodium Succinate

Reproductive & Fertility-Females	Rat	Oral	210 mg/kg/day	LOAEL	Maternal toxicity
Embryo / Fetal Development	Mouse	Oral	10 mg/kg/day	LOAEL	Developmental toxicity

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### Hydrocortisone Sodium Succinate

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
<i>In Vivo In Vitro</i> Direct DNA Damage	Rat , Mouse	Positive
<i>In Vivo In Vitro</i> Chromosome Aberration	Rat , Mouse	Positive
Cytogenetics	Mouse	Negative

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties of the formulation have not been thoroughly investigated. Releases to the environment should be avoided.

### 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

**EU Symbol:** Xn  
**EU Indication of danger:** Toxic to Reproduction: Category 3

**EU Risk Phrases:** R63 - Possible risk of harm to the unborn child.

**EU Safety Phrases:**

100 MG PLAIN

## MATERIAL SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection

Revision date: 05-Nov-2009

Page 6 of 7

Version: 1.3

### 15. REGULATORY INFORMATION

S22 - Do not breathe dust.  
S36/37 - Wear suitable protective clothing and gloves.  
S53 - Avoid exposure - obtain special instructions before use.

#### OSHA Label:

WARNING

Suspected of damaging the unborn child.

#### Canada - WHMIS: Classifications

##### WHMIS hazard class:

Class D, Division 2, Subdivision A



#### Hydrocortisone Sodium Succinate

Australia (AICS):	Listed
EU EINECS/ELINCS List	204-725-5

#### Sodium phosphate, monobasic

Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	231-449-2

#### Sodium phosphate, dibasic

CERCLA/SARA Hazardous Substances and their Reportable Quantities:	2270 kg final RQ 5000 lb final RQ
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	231-448-7

### 16. OTHER INFORMATION

#### Text of R phrases mentioned in Section 3

R63 - Possible risk of harm to the unborn child.

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients.

**Reasons for Revision:** Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

## MATERIAL SAFETY DATA SHEET

**Material Name:** Hydrocortisone Sodium Succinate for  
Injection

**Revision date:** 05-Nov-2009

**Page 7 of 7**

**Version:** 1.3

---

**Prepared by:**

Toxicology and Hazard Communication  
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**





# SAFETY DATA SHEET

Revision date: 01-Nov-2014

Version: 2.1

Page 1 of 8

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Hydrocortisone Sodium Succinate for Injection

**Trade Name:** Solu-Cortef; HYDROCORTISON

**Synonyms:** Hydrocortisone sodium succinate Powder For Solution For Injection or Infusion, IM/IV

**Chemical Family:** Mixture

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as anti-inflammatory

### Details of the Supplier of the Safety Data Sheet

Pfizer Inc  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-800-879-3477

Pfizer Ltd  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161

**Emergency telephone number:**  
**CHEMTREC (24 hours):** 1-800-424-9300  
**Contact E-Mail:** pfizer-MSDS@pfizer.com

**Emergency telephone number:**  
**International CHEMTREC (24 hours):** +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Reproductive Toxicity: Category 2

#### US OSHA Specific - Classification

**Physical Hazard:** Combustible Dust

#### EU Classification:

EU Indication of danger: Toxic to Reproduction: Category 3

EU Risk Phrases:

R63 - Possible risk of harm to the unborn child.

### Label Elements

**Signal Word:** Warning

**Hazard Statements:** H361d - Suspected of damaging the unborn child  
May form combustible dust concentrations in air

#### Precautionary Statements:

P201 - Obtain special instructions before use  
P202 - Do not handle until all safety precautions have been read and understood  
P281 - Use personal protective equipment as required  
P308 + P313 - IF exposed or concerned: Get medical attention/advice  
P405 - Store locked up  
P501 - Dispose of contents/container in accordance with all local and national regulations

100 MG PLAIN

## SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection  
Revision date: 01-Nov-2014

Page 2 of 8

Version: 2.1



Other Hazards  
Australian Hazard Classification (NOHSC):

No data available  
Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

#### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Hydrocortisone Sodium Succinate	125-04-2	204-725-5	Repr.Cat.3;R63	Repr. 2 (H361d)	91.3

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Sodium phosphate, monobasic	7558-80-7	231-449-2	Not Listed	Not Listed	*
Sodium phosphate, dibasic	7558-79-4	231-448-7	Not Listed	Not Listed	*

**Additional Information:** \* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.  
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

#### Description of First Aid Measures

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

100 MG PLAIN

## SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection

Revision date: 01-Nov-2014

Page 3 of 8

Version: 2.1

### Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure:	None known

### Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:	None
---------------------	------

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Carbon dioxide, carbon monoxide

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** No data available

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Control Parameters

100 MG PLAIN

## SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection

Revision date: 01-Nov-2014

Page 4 of 8

Version: 2.1

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hydrocortisone Sodium Succinate

Pfizer OEL TWA-8 Hr:

100µg/m<sup>3</sup>, Skin

#### Exposure Controls

##### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

##### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

##### Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

##### Eyes:

Wear safety glasses or goggles if eye contact is possible.

##### Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

##### Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

#### Physical State:

Powder

#### Color:

White to off-white

#### Odor:

No data available.

#### Odor Threshold:

No data available.

#### Molecular Formula:

Mixture

#### Molecular Weight:

Mixture

#### Solvent Solubility:

No data available

#### Water Solubility:

No data available

#### Solubility:

Soluble: Water

#### pH:

No data available.

#### Melting/Freezing Point (°C):

No data available

#### Boiling Point (°C):

No data available.

#### Partition Coefficient: (Method, pH, Endpoint, Value)

#### Hydrocortisone Sodium Succinate

No data available

#### Sodium phosphate, dibasic

No data available

#### Sodium phosphate, monobasic

No data available

#### Decomposition Temperature (°C):

No data available.

#### Evaporation Rate (Gram/s):

No data available

#### Vapor Pressure (kPa):

No data available

#### Vapor Density (g/ml):

No data available

#### Relative Density:

No data available

#### Viscosity:

No data available

#### Flammability:

##### Autoignition Temperature (Solid) (°C):

No data available

##### Flammability (Solids):

No data available

##### Flash Point (Liquid) (°C):

No data available

##### Upper Explosive Limits (Liquid) (% by Vol.):

No data available

##### Lower Explosive Limits (Liquid) (% by Vol.):

No data available

## SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection  
Revision date: 01-Nov-2014

Page 5 of 8

Version: 2.1

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available  
**Chemical Stability:** Stable under recommended storage conditions. Solutions are unstable after 4 hours.  
**Possibility of Hazardous Reactions**  
**Oxidizing Properties:** No data available  
**Conditions to Avoid:** Exposure to light  
**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers  
**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

**Short Term:** May cause slight irritation ; May cause skin irritation. (based on components) . May be absorbed through the skin in harmful amounts. Central nervous system effects such as headache, dizziness, drowsiness, fatigue, and lack of muscular coordination can also occur. May cause stomach irritation, diarrhea, nausea, or vomiting.

**Long Term:** Animal studies have shown a potential to cause adverse effects on the fetus. However, occupational handling of this product is not expected to result in relevant exposures.

**Known Clinical Effects:** Effects on vision have been seen during clinical use. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual irregularities, facial hair growth, and mental changes. Clinical use may cause an increase in blood pressure (hypertension). Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Hydrocortisone Sodium Succinate

Rat Oral LD 50 5000 mg/kg  
Mouse Oral LD 50 5000mg/kg  
Rat Subcutaneous LD 50 449mg/kg  
Mouse Subcutaneous LD 50 >500mg/kg  
Rat Intraperitoneal LD 50 150mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Hydrocortisone Sodium Succinate

Eye Irritation Rabbit Minimal

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Hydrocortisone Sodium Succinate

7 Day(s) Mouse Oral 140 mg/kg/day LOAEL Thymus  
4 Day(s) Mouse Subcutaneous 100 mg/kg/day LOAEL Liver  
11 Day(s) Mouse Subcutaneous 62 mg/kg/day LOAEL Endocrine system  
2 Week(s) Mouse Subcutaneous 560 mg/kg/day LOAEL Liver, Bone Marrow  
85 Day(s) Rat Subcutaneous 175 mg/kg/day LOAEL Adrenal gland

100 MG PLAIN

## SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection

Revision date: 01-Nov-2014

Page 6 of 8

Version: 2.1

### 11. TOXICOLOGICAL INFORMATION

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### Hydrocortisone Sodium Succinate

Reproductive & Fertility-Females	Rat	Oral	210 mg/kg/day	LOAEL	Maternal toxicity
Embryo / Fetal Development	Mouse	Oral	10 mg/kg/day	LOAEL	Developmental toxicity

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### Hydrocortisone Sodium Succinate

Bacterial Mutagenicity (Ames)	Salmonella	Negative
In Vivo In Vitro Direct DNA Damage	Rat , Mouse	Positive
In Vivo In Vitro Chromosome Aberration	Rat , Mouse	Positive
Cytogenetics	Mouse	Negative

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### 12. ECOLOGICAL INFORMATION

<b>Environmental Overview:</b>	Environmental properties of the formulation have not been thoroughly investigated. Releases to the environment should be avoided.
<b>Toxicity:</b>	No data available
<b>Persistence and Degradability:</b>	No data available
<b>Bio-accumulative Potential:</b>	No data available
<b>Mobility in Soil:</b>	No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection

Revision date: 01-Nov-2014

Page 7 of 8

Version: 2.1

### 15. REGULATORY INFORMATION

#### Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

##### Canada - WHMIS: Classifications

##### WHMIS hazard class:

Class D, Division 2, Subdivision A



##### Hydrocortisone Sodium Succinate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	204-725-5

##### Sodium phosphate, monobasic

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-449-2

##### Sodium phosphate, dibasic

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb 2270 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-448-7

### 16. OTHER INFORMATION

#### Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

Toxic to Reproduction: Category 3

R63 - Possible risk of harm to the unborn child.

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients.

**Reasons for Revision:** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

100 MG PLAIN

## SAFETY DATA SHEET

**Material Name:** Hydrocortisone Sodium Succinate for  
Injection

**Page 8 of 8**

**Revision date:** 01-Nov-2014

**Version:** 2.1

---

**Revision date:**

01-Nov-2014

Product Stewardship Hazard Communication

**Prepared by:**

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**